Trials / Terminated
TerminatedNCT05653427
A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
A Phase 2, Open-Label Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize the preliminary antitumor activity of amivantamab at the recommended dose in participants with previously systemically treated hepatocellular carcinoma (HCC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amivantamab | Amivantamab will be administered intravenously. |
Timeline
- Start date
- 2022-12-08
- Primary completion
- 2023-10-10
- Completion
- 2023-10-10
- First posted
- 2022-12-16
- Last updated
- 2025-01-13
- Results posted
- 2024-10-30
Locations
13 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05653427. Inclusion in this directory is not an endorsement.